Miss Chen

Miss Chen

OVERVIEW

Name: Miss Chen
Diagnosis: Diabetes
D.O.B: 01 March 1990
Gender: Female
Country: China

Treatment: cellular treatment for type 1 diabetes with Mesenchymal cells (MSCs) injections.

HISTORY

Patient Chen was a 22-year-old female who was admitted to Puhua International Hospital in China for Cellular Treatment of Type-1 Diabetes. Her life changed in December 2003, with a diagnosis of diabetes, accompanied bydiabetic ketoacidosis (DKA). She suffered from typical symptoms of diabetes:  feelings of thirst, increased hunger, frequent urination, and loss of weight. She lost more than ten kilos in three days before her diagnosis. She searched treatments from many big hospitals:  even insulin injections could not control her blood glucose well. Patient Chen found herself in a very unstable condition. On 23th March 2010, she was transferred to Beijing Ruijing Diabetes Hospital. She was placed on a diabetic diet and other therapy, meanwhile, she was using Insulin Novorapid 30R Injection for 20 units before breakfast, 10 units before lunch, and 20 units before supper. Her blood glucose was still unstable. With a hope for a more definitive treatment, she visited Beijing Tiantan Puhua International Hospital.

Medical Condition before Cellular Treatment for Type-1 Diabetes:

Prior to Cellular Treatment, her fasting plasma glucose (FPG) was controlled at a level of 6.4-13.8mmol/L. The glycosylated haemoglobin (HbA1C) was 8.4, which meant that her blood glucose was under poor control over the previous 3 months. She was thin, with a weight of 54 kilos, and a height of 170 cm. Her appetite was normal, as well as her sleep quality. The main problem with Patient Chen was her unstable blood glucose.

Cellular Treatment for Type-1 Diabetes:

Patient Chen received four injections of mesenchymal cells (msc).

Medical Condition after Cellular Treatment for Type-1 Diabetes:

After four injections of mesenchymal cells, her blood glucose level improved significantly. Not only was her blood glucose under a stable control, but also the dosage of insulin began to decrease. Her FPG was almost normal, with a level of 4.7-6.7mmol/L. Her postprandial blood glucose was much better and more stable than before too, with a level of 4.2-9.1mmol/L. She received these improvements within 15 days.  Glycosylated hemoglobin (HbA1C) only 15 days after treatment decreased to 7.1, which was much lower than the initial one of 8.4. Cellular Treatment also lowered her dosage of insulin (Novorapid 30R). Before Cellular Treatment, she used 50 units a day. After the treatment, she just needed 40 units a day, and her blood glucose was much stable.  Given the  better control of blood glucose, her lower glycosylated haemoglobin (HbA1C), and the lower dosage of insulin, Patient Chen and her family were very satisfied with the treatment. Miss Chen and her family were eager to see more improvements following the Cellular Treatment.

Follow Up

One month after Patient Chen’s discharge, her blood glucose was stable.  FPG was at a level of 4.1-5.9mmol/L. Postprandial blood glucose is much the same as her discharge level. The dosage of insulin had been reduced from 40 units to 37 units a day.

Cellular treatment for type 1 diabetes-FPG of Miss

misschenfig1

After cellular therapy, Miss Chen' FPG is well controlled.

misschenfig2.jpg

After cellular therapy, Miss Chen' 2hPG is much lower.

Cellular treatment for type 1 diabetes-HbA1C

After cellular therapy, Miss Chen' HBA1C is 7.1, much lower then the before condition, with a level of 8.4.

misschenfig4.jpg

 

Cellular treatment for type 1 diabetes-C peptide release test of Miss Chen

misschenfig5.jpg

Both insulin release test and C peptide release test are improved, which means that her pancreas function is better now.

Joomla SEO by AceSEF